This limitation has been addressed above as a future direction for additional clinical trials, such as DESTINY-Breast09, to investigate the potential of ADCs as first-line therapy for ERBB2-positive metastatic BC with direct comparison to trastuzumab-containing standard regimens with respect to their clinical efficacy and safety profile. Here, ERBB2 is linked to breast cancer.